Amalio Telenti

Q: What Schools Are Affiliated With Amalio Telenti

Amalio Telenti is affiliated with the following schools: Duke University, University of Western Australia, University of Lausanne, University of California, San Diego, Hannover Medical School, Stanford University, Baylor College of Medicine, University of Bern

Amalio Telenti's AcademicInfluence.com Rankings

Amalio Telenti

Biology

#6207

World Rank

#8873

Historical Rank

Bioinformatics

#64

World Rank

#65

Historical Rank

Computational Biology

#103

World Rank

#103

Historical Rank

Molecular Biology

#624

World Rank

#639

Historical Rank

biology Degrees

Download Badge

Biology

Amalio Telenti's Degrees

PhD Bioinformatics University of California, San Diego
Masters Computer Science Stanford University

Similar Degrees You Can Earn

Best Online Master's in Computer Science

Why Is Amalio Telenti Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Amalio Telenti's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. (2008) (2385)
Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis (1993) (1485)
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody (2020) (1411)
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis (1993) (1297)
A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 (2007) (1258)
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. (2010) (1216)
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation (2010) (1129)
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study (1999) (989)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients (2001) (901)
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1 (2007) (746)
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. (2012) (742)
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift (2021) (670)
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. (1999) (646)
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. (1999) (524)
Towards an HIV cure: a global scientific strategy (2012) (520)
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations (1994) (484)
A primer on deep learning in genomics (2018) (461)
The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol (1997) (450)
Common Genetic Variation and the Control of HIV-1 in Humans (2009) (448)
Critical role for the chemokine receptor CXCR 6 in NK cell – mediated antigen-specific memory of haptens and viruses (2010) (447)
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity (2021) (443)
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. (2014) (435)
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients (2005) (427)
Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis (1998) (418)
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. (2003) (410)
Critical role for CXCR6 in NK cell-mediated antigen-specific memory to haptens and viruses (2010) (388)
The fecal metabolome as a functional readout of the gut microbiome (2018) (386)
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) (1998) (367)
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 (2021) (358)
Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level (1997) (349)
A novel insertion element from Mycobacterium avium, IS1245, is a specific target for analysis of strain relatedness (1995) (331)
Differential microRNA regulation of HLA-C expression and its association with HIV control (2011) (319)
Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations (1997) (319)
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 (2021) (314)
HIV entry inhibitors (2007) (302)
Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy (2001) (300)
Deep sequencing of 10,000 human genomes (2016) (293)
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection (2003) (288)
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern (2021) (283)
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C (2009) (283)
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. (1999) (282)
Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites (2017) (275)
Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals (2007) (271)
Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis (1993) (265)
Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study (1999) (261)
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance (2001) (257)
Update of the drug resistance mutations in HIV-1: Fall 2005. (2005) (254)
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape (2021) (251)
Genotypic Analysis of Mycobacterium tuberculosis in Two Distinct Populations Using Molecular Beacons: Implications for Rapid Susceptibility Testing (2000) (247)
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. (2001) (244)
Crystal structure of GyrA intein from Mycobacterium xenopi reveals structural basis of protein splicing (1998) (244)
Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells (2014) (232)
The blood DNA virome in 8,000 humans (2017) (214)
Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides (2012) (213)
APOBEC3G Genetic Variants and Their Influence on the Progression to AIDS (2004) (208)
Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. (1995) (207)
Cohort profile: the Swiss HIV Cohort study. (2010) (204)
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. (2005) (203)
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. (2014) (203)
HIV treatment failure: testing for HIV resistance in clinical practice. (1998) (199)
After the pandemic: perspectives on the future trajectory of COVID-19 (2021) (197)
Molecular approach to identifying route of transmission of tuberculosis in the community (1993) (192)
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. (1999) (190)
Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. (2011) (190)
The Human Microbiome and Cancer (2017) (187)
Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. (2012) (186)
Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk (2019) (183)
WGAViewer: software for genomic annotation of whole genome association studies. (2008) (179)
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. (2003) (177)
Genome-Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-1-Infected Individuals (2010) (173)
Broad betacoronavirus neutralization by a stem helix–specific human antibody (2021) (173)
Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 Infectivity. (2016) (167)
Addressing the concerns of the lacks family: quantification of kin genomic privacy (2013) (167)
Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection (2007) (165)
Role of embB in natural and acquired resistance to ethambutol in mycobacteria (1997) (161)
Update of the Drug Resistance Mutations in HIV-1: 2005. (2005) (160)
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies (2021) (159)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function (2009) (159)
Copy Number Variation of KIR Genes Influences HIV-1 Control (2011) (158)
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control (2013) (158)
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift (2021) (157)
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 (2022) (157)
Human gene essentiality (2017) (156)
Broad sarbecovirus neutralization by a human monoclonal antibody (2021) (153)
Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. (2002) (149)
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. (2002) (145)
Paternally inherited cis-regulatory structural variants are associated with autism (2018) (144)
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load (2015) (140)
Lausannevirus, a giant amoebal virus encoding histone doublets. (2011) (139)
24 Hours in the Life of HIV-1 in a T Cell Line (2013) (138)
Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov (1996) (137)
Identification of individuals by trait prediction using whole-genome sequencing data (2017) (137)
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. (2007) (136)
Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals (2009) (135)
Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. (2000) (134)
Hepatic cyst infection in autosomal dominant polycystic kidney disease. (1990) (134)
The Mycobacterium xenopi GyrA protein splicing element: characterization of a minimal intein (1997) (134)
Contribution of kasA Analysis to Detection of Isoniazid-Resistant Mycobacterium tuberculosisin Singapore (1999) (133)
Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls (2013) (133)
Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load (2010) (133)
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429 (2021) (128)
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. (2009) (127)
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population (2003) (123)
Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies (1997) (122)
Candidemia from a urinary tract source: microbiological aspects and clinical significance. (1993) (121)
Clinical Implications of Mycobacterium kansasii Species Heterogeneity: Swiss National Survey (2003) (121)
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. (2005) (121)
Transplacental passage of protease inhibitors at delivery (2002) (120)
HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. (1999) (119)
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. (2005) (117)
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. (2002) (116)
Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection (2006) (114)
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir (2010) (113)
Structural and functional analysis of a potent sarbecovirus neutralizing antibody (2020) (112)
Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. (1995) (112)
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing (2014) (112)
The human noncoding genome defined by genetic diversity (2018) (110)
Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity (2004) (110)
Update of the drug resistance mutations in HIV-1: 2004. (2004) (110)
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. (2011) (109)
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. (2000) (108)
Drug resistance mutations in HIV-1. (2003) (108)
The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. (2008) (105)
Genetics of drug resistance in tuberculosis. (1997) (104)
The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity (2020) (103)
Profiling of Short-Tandem-Repeat Disease Alleles in 12,632 Human Whole Genomes (2017) (101)
Identification of Misclassified ClinVar Variants via Disease Population Prevalence. (2018) (100)
Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression (2010) (99)
Severe viral respiratory infections in children with IFIH1 loss-of-function mutations (2017) (99)
Comparison of phasing strategies for whole human genomes (2018) (97)
The decaying genome of Mycobacterium leprae. (2001) (96)
Individual Contributions of Mutant Protease and Reverse Transcriptase to Viral Infectivity, Replication, and Protein Maturation of Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1 (2001) (94)
Fast and accurate HLA typing from short-read next-generation sequence data with xHLA (2017) (92)
Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection (2006) (91)
HIV-1 Capture and Transmission by Dendritic Cells: The Role of Viral Glycolipids and the Cellular Receptor Siglec-1 (2014) (89)
Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects (2004) (88)
Innate immunogenetics: a tool for exploring new frontiers of host defence (2007) (86)
Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 Protein (2001) (84)
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy (2007) (83)
Role of common human TRIM5α variants in HIV-1 disease progression (2006) (83)
Genotypic characterization of Mycobacterium avium strains recovered from animals and their comparison to human strains (1995) (83)
PRINCESS: Privacy‐protecting Rare disease International Network Collaboration via Encryption through Software guard extensionS (2017) (81)
HIV-1 co/super-infection in intravenous drug users (2004) (81)
Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study. (2003) (81)
Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis (2000) (80)
Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses (2015) (78)
Infrequent Transmission of HIV-1 Drug-Resistant Variants (2003) (77)
Changes in renal function associated with indinavir (1998) (77)
Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo (2005) (76)
Structure-Function Analyses Point to a Polynucleotide-Accommodating Groove Essential for APOBEC3A Restriction Activities (2010) (76)
Orosomucoid (α1‐acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation (2006) (76)
In Vitro Whole-Genome Analysis Identifies a Susceptibility Locus for HIV-1 (2008) (74)
Microbial metagenome of urinary tract infection (2017) (74)
Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers (2010) (73)
Typing of Pneumocystis carinii f. sp. hominis by single-strand conformation polymorphism of four genomic regions (1997) (72)
Resurgence of HIV Infection among Men Who Have Sex with Men in Switzerland: Mathematical Modelling Study (2012) (72)
Pharmacogenetics of anti-HIV drugs. (2008) (72)
Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell Model (2014) (72)
Predicting the mutational drivers of future SARS-CoV-2 variants of concern (2021) (69)
HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells (2015) (68)
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients (2005) (68)
Genomics meets HIV-1 (2006) (68)
Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance (2011) (68)
Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease (2018) (67)
Analysis of HIV-1 Expression Level and Sense of Transcription by High-Throughput Sequencing of the Infected Cell (2011) (66)
Use of a Combined Ex Vivo/In Vivo Population Approach for Screening of Human Genes Involved in the Human Immunodeficiency Virus Type 1 Life Cycle for Variants Influencing Disease Progression (2005) (66)
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. (2013) (66)
Analysis of Natural Variants of the Human Immunodeficiency Virus Type 1 gag-pol Frameshift Stem-Loop Structure (2002) (64)
Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. (2007) (63)
Discovery and characterization of an endogenous CXCR4 antagonist. (2015) (63)
Evolutionary trajectories of primate genes involved in HIV pathogenesis. (2009) (62)
Quantitative blood cultures in candidemia. (1991) (61)
LILRB2 Interaction with HLA Class I Correlates with Control of HIV-1 Infection (2014) (61)
Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study (2004) (61)
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study (2014) (58)
Model Structure of Human APOBEC3G (2007) (58)
Identifying Adverse Effects of HIV Drug Treatment and Associated Sentiments Using Twitter (2015) (58)
Entry and Transcription as Key Determinants of Differences in CD4 T-Cell Permissiveness to Human Immunodeficiency Virus Type 1 Infection (2004) (57)
CCL3L1 and HIV/AIDS susceptibility (2009) (57)
Nelfinavir Plasma Levels Under Twice-Daily and Three-Times-Daily Regimens: High Interpatient and Low Intrapatient Variability (2001) (57)
Transcription Factor-Directed Re-wiring of Chromatin Architecture for Somatic Cell Nuclear Reprogramming toward trans-Differentiation. (2019) (56)
Stable virulence levels in the HIV epidemic of Switzerland over two decades (2006) (56)
The Evolution and Biology of SARS-CoV-2 Variants. (2022) (56)
Deep learning of genomic variation and regulatory network data. (2018) (55)
Host Genetics and HIV-1: The Final Phase? (2010) (54)
Genetics of drug resistant tuberculosis (1998) (54)
Sincell: an R/Bioconductor package for statistical assessment of cell-state hierarchies from single-cell RNA-seq (2015) (54)
Safety concerns about CCR5 as an antiviral target (2009) (53)
Mapping of positive selection sites in the HIV-1 genome in the context of RNA and protein structural constraints (2011) (53)
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. (2002) (53)
Liver enzyme elevation after lamivudine withdrawal in HIV–hepatitis B virus co‐infected patients: the Swiss HIV Cohort Study (2009) (53)
ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression. (2010) (52)
The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription (2006) (52)
CD 4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years The Swiss HIV Cohort Study (2003) (50)
Patterns of evolution of host proteins involved in retroviral pathogenesis (2006) (50)
Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study (2001) (50)
Protecting genomic data analytics in the cloud: state of the art and opportunities (2016) (50)
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. (2013) (49)
Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals: A Longitudinal Study (2009) (49)
Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy (2010) (49)
Disentangling Human Tolerance and Resistance Against HIV (2014) (47)
Efavirenz decreases methadone blood concentrations. (2000) (47)
Privacy-preserving genomic testing in the clinic: a model using HIV treatment (2016) (47)
Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. (2007) (47)
Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. (2001) (47)
Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals (2012) (46)
Ranking of non-coding pathogenic variants and putative essential regions of the human genome (2019) (46)
Protection from HIV-1 Infection of Primary Cd4 T Cells by Ccr5 Silencing is Effective for the Full Spectrum of Ccr5 Expression (2002) (45)
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. (2004) (45)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
[Acute pelvic inflammatory disease]. (1981) (44)
Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction (2008) (44)
The evolutionary history of the CD209 (DC-SIGN) family in humans and non-human primates (2008) (43)
Individualising HIV treatment—pharmacogenetics and immunogenetics (2002) (42)
A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. (2013) (42)
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7 (2007) (42)
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents (2006) (42)
Successful Efavirenz Dose Reduction Guided by Therapeutic Drug Monitoring (2011) (42)
Single-cell analysis identifies cellular markers of the HIV permissive cell (2017) (41)
Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients (2000) (41)
Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study (2000) (40)
Reconciling Utility with Privacy in Genomics (2014) (40)
Drug resistance in Mycobacterium tuberculosis. (1995) (38)
HIV-1 elite controllers: beware of super-infections. (2010) (38)
Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus (2004) (36)
Virological and immunological characteristics of HIV treatment failure (2000) (35)
Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case–control study from the Swiss HIV Cohort (2002) (35)
Drug-resistant tuberculosis: what do we do now? (2000) (34)
Evaluation of the rpoB gene in rifampicin-susceptible and -resistant Mycobacterium avium and Mycobacterium intracellulare. (1994) (34)
Quantifying Interdependent Risks in Genomic Privacy (2017) (34)
CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. (2004) (34)
Ritonavir-Boosted Atazanavir-Lopinavir Combination: A Pharmacokinetic Interaction Study of Total, Unbound Plasma and Cellular Exposures (2006) (34)
A community effort to protect genomic data sharing, collaboration and outsourcing (2017) (34)
Idiopathic granulomatosis manifesting as fever of unknown origin. (1989) (34)
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection (2000) (33)
Consistent Effects of TSG101 Genetic Variability on Multiple Outcomes of Exposure to Human Immunodeficiency Virus Type 1 (2006) (33)
Antiretroviral therapies from the patient's perspective (2000) (32)
Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? (2008) (32)
Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control (2015) (32)
Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study (2001) (32)
Toxicogenetics of Antiretroviral Therapy: Genetic Factors that Contribute to Metabolic Complications (2007) (32)
Polymicrobial fungemia: microbiology, clinical features, and significance. (1989) (32)
Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals. (2010) (32)
The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case–control study (2004) (31)
Free and Total Plasma Levels of Lopinavir during Pregnancy, at Delivery and Postpartum: Implications for Dosage Adjustments in Pregnant Women (2012) (31)
HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. (2008) (31)
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. (2014) (31)
Unique Spectrum of Activity of Prosimian TRIM5α against Exogenous and Endogenous Retroviruses (2011) (31)
Competitive polymerase chain reaction using an internal standard: application to the quantitation of viral DNA. (1992) (31)
Single-Cell Genomics for Virology (2016) (30)
Entry of Polarized Effector Cells into Quiescence Forces HIV Latency (2019) (30)
Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. (2002) (30)
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape (2021) (30)
Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy (2011) (30)
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid (2016) (30)
Antiretroviral Activity of Ancestral TRIM5α (2007) (29)
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals (2013) (29)
Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics. (2010) (29)
Analysis of Stop-Gain and Frameshift Variants in Human Innate Immunity Genes (2014) (29)
Human Immunodeﬁciency Virus Type 1 Fitness Is a Determining Factor in Viral Rebound and Set Point in Chronic Infection (2003) (29)
Establishing the involvement of the novel gene AGBL5 in retinitis pigmentosa by whole genome sequencing. (2016) (29)
A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae. (1993) (29)
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody (2020) (29)
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. (2011) (29)
A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART (2003) (28)
Counteraction of HLA-C-Mediated Immune Control of HIV-1 by Nef (2010) (28)
The Characteristics of Heterozygous Protein Truncating Variants in the Human Genome (2015) (28)
Silencing of both β-TrCP1 and HOS (β-TrCP2) Is Required To Suppress Human Immunodeficiency Virus Type 1 Vpu-Mediated CD4 Down-Modulation (2006) (28)
Functional characterization of 3D protein structures informed by human genetic diversity (2017) (28)
Promoter polymorphisms and allelic imbalance in ABCB1 expression (2007) (27)
Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. (2001) (27)
Identification of Siglec-1 null individuals infected with HIV-1 (2016) (27)
Acetaminophen (Paracetamol) Use Modifies the Sulfation of Sex Hormones (2018) (26)
Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy (2012) (26)
Infectious diseases not immune to genome-wide association (2010) (26)
ADME pathway approach for pharmacogenetic studies of anti-HIV therapy. (2007) (26)
MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment. (2004) (26)
Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller (2012) (25)
Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy. (2001) (25)
The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors. (1999) (25)
HumanImmunodeficiency Virus Type 1 Fitness Is a Determining Factor in ViralRebound and Set Point in ChronicInfection (2003) (25)
Drug-Resistant Tuberculosis (1989) (25)
New Insights into the Genetic Basis of Monge’s Disease and Adaptation to High-Altitude (2017) (24)
Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. (1996) (24)
Host genes important to HIV replication and evolution. (2012) (23)
Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland (2017) (23)
Epstein-Barr virus infection in HIV-positive patients (1993) (23)
Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir (2013) (23)
Limits to potent antiretroviral therapy (2000) (22)
On Non-cooperative Genomic Privacy (2015) (22)
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis (2015) (22)
Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies (2021) (22)
Susceptibility to HIV infection--disentangling host genetics and host behavior. (2006) (22)
The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. (2015) (22)
The DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction (2003) (21)
Genetic Diversity of EBV-Encoded LMP1 in the Swiss HIV Cohort Study and Implication for NF-Κb Activation (2012) (21)
The Antiviral Activity of the Cellular Glycoprotein LGALS3BP/90K Is Species Specific (2018) (21)
Are Plasma Levels Valid Surrogates for Cellular Concentrations of Antiretroviral Drugs in HIV-infected Patients? (2006) (21)
Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. (2007) (20)
Spare non-occupational HIV post-exposure prophylaxis by active contacting and testing of the source person (2002) (20)
Molecular Epidemiology of Tuberculosis among HIV-Infected Persons in Switzerland: A Countrywide 9-Year Cohort Study (1999) (20)
SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells (2021) (20)
Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression (2014) (19)
SAMHD 1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage (2014) (19)
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics (2011) (19)
Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. (2006) (18)
Innate immune defects in HIV permissive cell lines (2016) (18)
Proteo-Transcriptomic Dynamics of Cellular Response to HIV-1 Infection (2019) (18)
The role of tripartite motif family members in mediating susceptibility to HIV-1 infection. (2012) (18)
Adaptation, co-evolution, and human susceptibility to HIV-1 infection. (2005) (18)
Exploring viral infection using single-cell sequencing. (2017) (18)
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody (2021) (18)
Does Tenofovir Influence Efavirenz Pharmacokinetics? (2007) (17)
High frequency of alternative splicing of human genes participating in the HIV-1 life cycle: a model using TSG101, betaTrCP, PPIA, INI1, NAF1, and PML. (2003) (17)
Impact of phenotype definition on genome-wide association signals: empirical evaluation in human immunodeficiency virus type 1 infection. (2011) (17)
Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein (2020) (17)
Inteins in mycobacterial GyrA are a taxonomic character. (1998) (17)
Comparison of random amplified polymorphic DNA with restriction fragment length polymorphism as epidemiological typing methods for Mycobacterium tuberculosis (1995) (16)
A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery (2021) (16)
Fungal blood cultures (1989) (16)
The Genomic Signature of Population Reconnection Following Isolation: From Theory to HIV (2015) (16)
Advances in Genomics for Drug Development (2020) (16)
Treating medical data as a durable asset (2020) (16)
The central region of human immunodeficiency virus type 1 p6 protein (Gag residues S14-I31) is dispensable for the virus in vitro. (2004) (15)
IFT88 mutations identified in individuals with non-syndromic recessive retinal degeneration result in abnormal ciliogenesis (2018) (15)
Correction (1975) (15)
Mycobacterial genome structure (minireview) (1998) (15)
Genomic determinants of the efficiency of internal ribosomal entry sites of viral and cellular origin (2008) (15)
Genomic approaches to the study of HIV‐1 acquisition. (2010) (15)
Susceptibility and adaptation to human TRIM5α alleles at positive selected sites in HIV-1 capsid. (2013) (14)
Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases (2011) (14)
Regulatory genome variants in human susceptibility to infection (2019) (13)
Whole Genome Sequencing Revealed Mutations in Two Independent Genes as the Underlying Cause of Retinal Degeneration in an Ashkenazi Jewish Pedigree (2017) (13)
Host genetics of HIV-1 susceptibility (2006) (13)
No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. (2011) (13)
Paternally inherited noncoding structural variants contribute to autism (2017) (12)
HIV-1 host interactions: integration of large-scale datasets (2009) (12)
Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. (1998) (12)
Genetic Methods For Detecting Bacterial Resistance Genes (2001) (12)
Evolutionary genomics and HIV restriction factors. (2015) (12)
Molecular techniques in the diagnosis of drug-resistant tuberculosis. (1997) (12)
Heterogeneity in the Response to Antiretroviral Therapy (2001) (12)
Bioinformatics and HIV Latency (2015) (12)
HIV-1 progression in hepatitis-C-infected drug users (2001) (12)
CCTTT‐repeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis (2004) (11)
An epidemic of blindness: a consequence of improved HIV care? (2001) (11)
Spare post-exposure prophylaxis with round-the-clock HIV testing of the source patient. (2001) (11)
GuavaH: a compendium of host genomic data in HIV biology and disease (2014) (11)
Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis. (2003) (11)
Peripheral oedema and high arterial blood flow as a complication of antiretroviral therapy. (2004) (10)
New developments in laboratory monitoring of HIV-1 infection. (2002) (10)
HIV and innate immunity – a genomics perspective (2013) (10)
Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant. (2018) (10)
On genomics, kin, and privacy (2014) (10)
HIV: The mixed blessing of interferon (2014) (10)
Dosage optimization of treatments using population pharmacokinetic modeling and simulation. (2012) (10)
Genomics of host-pathogen interactions. (2014) (10)
Pulsed field gel electrophoresis for mycobacteria. (1998) (9)
Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses (2021) (9)
Discontinuation of Prophylaxis against Opportunistic Infections in HIV-Infected Persons Receiving Potent Combination Antiretroviral Therapy (2001) (9)
Evaluation of the relatedness of strains ofMycobacterium avium using pulsed-field gel electrophoresis (1995) (9)
Host factors associated with outcome from primary human immunodeficiency virus-1 infection (2008) (9)
Genetic screening for metabolic and age-related complications in HIV-infected persons (2010) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
Development of a Molecular Typing Method for Pneumocystis carinii sp.f. hominis (1996) (8)
Dynamics of an Aging Genome. (2016) (8)
Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein (2021) (8)
LILRB 2 Interaction with HLA Class I Correlates with Control of HIV-1 Infection (2014) (8)
Efavirenz Intoxication Due to a New Cyp2B6 Constellation (2013) (8)
Retroviruses As Myeloid Cell Riders: What Natural Human Siglec-1 “Knockouts” Tell Us About Pathogenesis (2017) (8)
More on "what's in a name ... "--pragmatism in mycobacterial taxonomy. (1998) (8)
Interactions of processed Nef (58-206) with virion proteins of HIV type 1. (2004) (8)
Novel insight into the genetic basis of high-altitude pulmonary hypertension in Kyrgyz highlanders (2018) (8)
Principles of Pharmacogenetics and Pharmacogenomics: HIV and Antiretroviral Therapy (2012) (7)
Detection of mutations in mycobacteria by PCR-SSCP (single-strand conformation polymorphism). (1998) (7)
Typing of Pneumocystis carinii sp.f. hominis by PCR‐SSCP of Four Genomic Regions (1997) (7)
HLA and HIV: modeling adaptation to moving targets (2003) (7)
Rethinking the medical record (2018) (7)
The human functional genome defined by genetic diversity (2016) (7)
A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease. (2011) (7)
Proceedings of the Frontiers of Retrovirology Conference 2016 (2016) (7)
Identifying Safety Concerns from Genetic Data: Lessons from the Development of CCR5 Inhibitors (2007) (6)
Machine Learning to Decode Genomics. (2019) (6)
Persistence of pneumococcal antigens in sputum after treatment of pneumonia. (1984) (6)
Identification of misclassified ClinVar variants using disease population prevalence (2016) (6)
Potential Coinfections Complicate Typing of Pneumocystis carinii f. sp. hominis (1998) (6)
State of genomics and epigenomics research in the perspective of HIV cure (2013) (6)
AssociationViewer: a scalable and integrated software tool for visualization of large-scale variation data in genomic context (2009) (6)
Resistance to New Anti-HIV Agents: Problems in the Pathway of Drug Registration (2005) (5)
Faculty Opinions recommendation of The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. (2007) (5)
Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles (2021) (5)
The genetic cohorts: facing the new challenges in infectious diseases. The HIV model. (2004) (5)
CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study (2010) (5)
HIV lipoatrophy and mosquito bites. (2002) (5)
Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry (2014) (5)
[Epidemiology of HIV-1 infection in Bern--application of molecular methods]. (1994) (5)
SOCIAL COST OF HIV INFECTION IN SWITZERLAND FINAL REPORT (5)
The Role of Antimicrobial Therapy (1998) (5)
Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor‐naive HIV‐infected patients: the Swiss HIV Cohort Study (2002) (5)
Integrating metabolomics with genomics. (2018) (5)
Time (again) for a randomized trial of pharmacogenetics of antiretroviral therapy. (2009) (4)
Identification of essential regulatory elements in the human genome (2018) (4)
Correction: 24 Hours in the Life of HIV-1 in a T Cell Line (2015) (4)
Correction: Copy Number Variation of KIR Genes Influences HIV-1 Control (2011) (4)
No major flaws in “Identification of individuals by trait prediction using whole-genome sequencing data” (2017) (4)
GenoShare: Supporting Privacy-Informed Decisions for Sharing Exact Genomic Data (2017) (4)
Host polymorphism in steps of the HIV-1 lifecycle after entry and other genetic variants influencing HIV-1 pathogenesis (2006) (4)
Conceptos generales y métodos de estudio en farmacogenética (2008) (4)
Impaired absorption of rifabutin by concomitant administration of didanosine. (2001) (4)
Adaptive immunity mediated by Natural Killer cells. (2012) (4)
[An update on hepatitis E]. (2013) (3)
Persistence of Pneumococcal Antigens in Sputum after Treatment of Pneumonia (1984) (3)
[GESIDA Consensus document on the use of resistance studies in clinical practice]. (2001) (3)
Simulating patient matching to clinical trials using a property rights blockchain (2020) (3)
Autism , bowel inflammation , and measles (3)
Development of a molecular typing method for Pneumocystis carinii sp.f. hominis (1997) (3)
Profound perturbation of the human metabolome by obesity (2018) (3)
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA (2023) (3)
Erratum: Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection (Journal of Virology (2006) 80, 22, (11094-11104)) (2007) (3)
Impact of phenotype definition on genome-wide association signals: empirical evaluation in HIV-1 infection (2011) (3)
Transfer transcriptomic signatures for infectious diseases (2020) (3)
Antibody therapy reverses biological signatures of COVID-19 progression (2021) (3)
Molecular diagnostics for infectious diseases: where do we stand? (1994) (3)
Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites (2017) (3)
Proteomic Studies of Human Lymphocytes: New Insights into HIV Lymphocyte Infection? (2004) (3)
Multidrug resistance and response to antiretroviral treatment (2002) (3)
Protecting Personal Genome Privacy: Solutions from Information Security (2012) (3)
Faculty Opinions recommendation of SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. (2013) (2)
Epstein-Barr virus and lymphoproliferative disorders: Basic concepts and diagnostic approach (1991) (2)
European Genetic Diversity and Susceptibility to Pathogens (2014) (2)
[Giant-cell arteritis of temporal localization and hepatic granulomatosis]. (1977) (2)
Population pharmacokinetics and effects of indinavir in HIV infected patients (2003) (2)
Appendicitis: Spectrum of Bacteria and the Role of Antimicrobial Therapy (1996) (2)
Time Frame for Infectious Complications in the Surgical-Trauma Intensive-Care Unit (1996) (2)
Literature Review 2008 (2008) (2)
Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape (2022) (2)
Septicemia y shock séptico (1991) (1)
Population Pharmacokinetic Analysis and Pharmacogenetics (2012) (1)
Reply to Nettles et al. (2006) (1)
HIV Susceptibility Testing – Time for Standards (2003) (1)
Variation in the Antiretroviral Protein TRIM5alpha in humans (2006) (1)
GuavaH: a compendium of host genomic data in HIV biology and disease (2014) (1)
A Bayesian network approach to study host and viral genetic correlates of HIV-1 disease progression (2011) (1)
The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice (2022) (1)
Response to Whiffin et al. (2019) (1)
Mycobacterium tuberculosis by Polymerase Chain Reaction (1)
Mapping of positive selection sites in the HIV genome in the context of RNA and protein structural constraints (2011) (1)
14. Antimicrobial Agents (2012) (1)
Polymorphisms, Resistance and Drug Response: Beyond Subtype-B HIV-1 (2004) (1)
Consistent Effects of TSG 101 Genetic Variability on Multiple Outcomes of Exposure to Human Immunodeficiency Virus Type 1 † (2018) (1)
Year : 2010 Genome-wide mRNA expression correlates of viral control in CD 4 + T-cells from HIV-1-infected individuals (2011) (1)
P701 AUTOCHTHONOUS ACUTE HEPATITIS E IN SWITZERLAND: INCREASED RATE OF SEVERE MANIFESTATION IN MEN >50 YEARS (2014) (1)
MP-NeRF: A Massively Parallel Method for Accelerating Protein Structure Reconstruction from Internal Coordinates (2021) (1)
Pharmacogenomics in HIV Disease (2008) (1)
Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification (2007) (1)
Fine population structure analysis method for genomes of many (2017) (1)
Genomics of HIV infection. (2015) (1)
[The EBNA2 coding region in the viral genome of Epstein-Barr virus (EBV)-positive cases of Hodgkin's disease]. (1992) (1)
Recommendations of the International AIDS Antiretroviral Treatment of Adult HIV Infection : 2008 (2008) (1)
Homozygosity Is Associated with an Impaired CD 4 T Cell Recovery after Initiation of Antiretroviral Therapy (2008) (1)
Interdependent Privacy Games: The Case of Genomics (2015) (1)
Transcriptional Proﬁling of CD4 T Cells Identiﬁes Distinct Subgroups of HIV-1 Elite Controllers (cid:1) † (2011) (1)
Proteo-Transcriptomic Dynamics of Cellular Response to HIV-1 Infection (2019) (1)
Analysis of Brugada syndrome loci reveals that fine-mapping clustered GWAS hits enhances the annotation of disease-relevant variants (2021) (1)
Abstract 205, 13th Conference on Retroviruses and Opportunistic Infections Denver, USA (2006) (1)
Chapter 14 Detection of mutations by PCR-single-strand conformation polymorphism (1995) (1)
[The genetics HIV cohort of the Swiss HIV Cohort Study--facing the new challenges in medicine]. (2004) (1)
Practical Solutions for Protecting Individual Genomic Privacy (2014) (0)
Genetic Associations with Resistance to HIV-1 Infection, Viral Control and Protection Against Disease (2012) (0)
ZNRD1 as a Host Cellular Factor Influencing HIV-1 Replication (2009) (0)
[HIV susceptibility determination: a qualified position against regarding a complex technology]. (2001) (0)
Heterozygous gene truncation delineates the human haploinsufficient genome (2014) (0)
Comparison of polymerase chain reaction (PCR), tuberculostearic acid (TBSA) and standard methods for diagnosing tuberculous meningitis. An in-vitro study (1993) (0)
Understanding the cellular function of SAMHD1: from HIV restriction to tumor suppression (2014) (0)
HEV as a cause of acute hepatitis acquired in Switzerland (2017) (0)
Host genome influences on susceptibility to HIV-1 (2009) (0)
Modelling HIV virulence evolution in the context of immune escape (2014) (0)
Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape (2022) (0)
Resource Profound Perturbation of t he Metabolome in Obesity Is Associated with Health Risk Graphical (2019) (0)
Retrieval of whole human genome clinical variant information through search motors (2019) (0)
Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein (2020) (0)
Humans Resembling Natural Hosts of SIV (2014) (0)
[HIV: epidemiology and treatment --2000]. (2000) (0)
HIV epidemiology and treatment - 1999. (1999) (0)
Nelfinavir plasma levels under tid and bid regimens: high inter- and low intra-patient variability. (2001) (0)
Host Response in HIV Infection (2016) (0)
Protecting genomic data analytics in the cloud: state of the art and opportunities (2016) (0)
Silencing of both (cid:2) -TrCP1 and HOS ( (cid:2) -TrCP2) Is Required To Suppress Human Immunodeﬁciency Virus Type 1 Vpu-Mediated CD4 Down-Modulation (cid:1) (2007) (0)
Proceedings of the Frontiers of Retrovirology Conference 2016 (2016) (0)
Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses (2015) (0)
Are estimates of CD4 decline from random effects models inherently biased due to missing data from rapid progressors (2005) (0)
Microbial metagenome of urinary tract infection (2018) (0)
[General concepts and study methods in pharmacogenetics]. (2008) (0)
Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection (2007) (0)
Nosocomial infections in the ICU (1995) (0)
IFT88 mutations identified in individuals with non-syndromic recessive retinal degeneration result in abnormal ciliogenesis (2018) (0)
Faculty Opinions recommendation of Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. (2013) (0)
Correction (2021) (0)
[Current developments in Mycobacteria diagnosis]. (1995) (0)
HIV Genomics: Bench to Bedside (2008) (0)
Host Genomic Profiling in Human Immunodeficiency Virus Infection (2011) (0)
Faculty Opinions recommendation of Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. (2009) (0)
Tuberculosis one century after R. Koch. (1998) (0)
Faculty Opinions recommendation of HIV rebounds from latently infected cells, rather than from continuing low-level replication. (2008) (0)
Abstract 1, 9th International Workshop on HIV, Budapest, Hungary (2005) (0)
Adaptive immunity mediated by Natural Killer cells. (45.20) (2012) (0)
Périard et al Lipids , Lp ( a ) , HIV , and Protease Inhibitors (1999) (0)
Faculty of 1000 evaluation for Human genome sequencing in health and disease. (2013) (0)
Activity of ancestral restriction factors against ancient retroviruses (2009) (0)
Nucleic acid amplification methods in diagnostic virology (1995) (0)
Post-HAART immunologic and virologic trends and carriage of HLA-Bw4: A comparison of the Western Australian and the Swiss HIV Cohort Studies (2006) (0)
G ENO S HARE : Using Avatars to Preserve Privacy on Genomics Pandora (2017) (0)
Joint analysis of host and pathogen genomes (2011) (0)
Faculty Opinions recommendation of Mapping copy number variation by population-scale genome sequencing. (2013) (0)
[Medicine faces the digital revolution]. (2015) (0)
Clinical use of pharmacogenomics (2012) (0)
Cloning andNucleotide Sequence ofMycobacterium tuberculosis gyrAandgyrBGenesandDetection ofQuinolone Resistance Mutations (1994) (0)
eview xploring viral infection using single-cell sequencing (2016) (0)
Highly active therapies from the patient's point of view. (2001) (0)
A community effort to protect genomic data sharing, collaboration and outsourcing (2017) (0)
Identification of pathogenic mutations in patients with inherited retinal dystrophies using whole genome sequencing (2017) (0)
Faculty Opinions recommendation of Intrinsic cellular defenses against human immunodeficiency viruses. (2013) (0)
[Antiviral therapy and resistance formation exemplified by HIV infection]. (2003) (0)
Comparison ofrandomamplified polymorphic DNA withrestriction fragment length polymorphism asepidemiological typing methods forMycobacterium tuberculosis (1995) (0)
Gene expression Sincell : an R / Bioconductor package for statistical assessment of cell-state hierarchies from single-cell RNA-seq (2015) (0)
The human noncoding genome defined by genetic diversity (2018) (0)
Faculty of 1000 evaluation for Rules of engagement: molecular insights from host-virus arms races. (2013) (0)
Mycobacterium avium a new emerging foodborne pathogen (1996) (0)
HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells (2015) (0)
Acknowledgement to Sponsors (2005) (0)
Sincell: R package for statistical assessment of cell state hierarchies from single-cell RNA-seq (2016) (0)
Presente y futuro de la virología clínica (2003) (0)
HIV entry inhibitors. Commentary (2007) (0)
patients with HIV disease A polymorphism in the leptin gene promoter is associated with anemia in (2012) (0)
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells (2022) (0)
A primer on deep learning in genomics (2018) (0)
Innate immune defects in HIV permissive cell lines (2016) (0)
Natural heteroclitic-like peptides are generated by SARS-CoV-2 mutations (2022) (0)
Diagnostic workup of the febrile ICU patient (1995) (0)
of Anti-HIV Drugs (2008) (0)
Sincell: Bioconductor package for the statistical assessment of cell-state hierarchies from single-cell RNA-seq data (2015) (0)
Comparative analysis of genomic features of human HIV-1 infection and primate models of SIV infection (2011) (0)
Analysis of HIV-1 Expression Level and Sense of Transcription by High-Throughput Sequencing of the Infected Cell (cid:1) (2011) (0)
Treating medical data as a durable asset (2020) (0)
Faculty Opinions recommendation of The evolution of gene duplications: classifying and distinguishing between models. (2013) (0)
Regulatory genome variants in human susceptibility to infection (2019) (0)
Contents Vol. 76, 2013 (2014) (0)
Correction: Gustafson et al., Whole Genome Sequencing Revealed Mutations in Two Independent Genes as the Underlying Cause of Retinal Degeneration in an Ashkenazi Jewish Pedigree. Genes 2017, 8, 210 (2017) (0)
Carriage of HLA-Bw4 is associated with lower CD4 cell counts after starting HAART: Consistent findings in the Western Australian HIV Cohort Study (WAHIV) and the Swiss HIV Cohort Study (SHCS). (2007) (0)
Human immunodeficiency virus-specific T lymphocyte cell (2001) (0)
CD4 changes in patients experiencing virological failure on a protease inhibitor-based regimen: the viral load/CD4 disconnect. (1999) (0)
Author Correction: Treating medical data as a durable asset (2020) (0)
[A primer on the management of antiviral resistance in chronic hepatitis B]. (2009) (0)
Identification of a novel SDCCAG8 gene variant in a family with retinitis pigmentosa and kidney failure (2017) (0)
Faculty of 1000 evaluation for Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. (2013) (0)
Premature peripheral atherosclerosis in HIV-infected patients (2001) (0)
Faculty Opinions recommendation of Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. (2009) (0)
Lessons from the first host-genome analyses in HIV (2008) (0)
Modelling CD4 cell counts in treated and untreated HIV positive patients according to genotype: methods to overcome selection and survivor bias (2003) (0)
Clinical use of pharmacogenomics (2012) (0)
The fecal metabolome as a functional readout of the gut microbiome (2018) (0)
Fine population structure analysis method for genomes of many (2017) (0)
Impact of Phenotype Deﬁnition on Genome-Wide Association Signals: Empirical Evaluation in Human Immunodeﬁciency Virus Type 1 Infection (2011) (0)
[Management of professional exposures to blood and other biological liquids contaminated with hepatitis B and C and HIV]. (1999) (0)
Correction (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Amalio Telenti?

Amalio Telenti is affiliated with the following schools:

Amalio Telenti's Academic­Influence.com Rankings

Amalio Telenti's Degrees

Similar Degrees You Can Earn

Why Is Amalio Telenti Influential?

Amalio Telenti's Published Works

Published Works

What Schools Are Affiliated With Amalio Telenti?

Amalio Telenti's AcademicInfluence.com Rankings